Skip to main content

Day: May 24, 2023

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 203Pb manufacturing, and In Vivo Distribution of Recoiled 213Bi from [225Ac]Ac-DOTATATE RICHLAND, WASHINGTON & CORALVILLE, Iowa, May 24, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will be presenting three posters at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) Annual Meeting being held in Hawaii from May 22-26, 2023. “We are thrilled...

Continue reading

Nautilus Biotechnology to Participate in Upcoming June Investor Conferences

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:Jefferies 2023 Healthcare Conference in New York, NY Fireside chat on Thursday, June 8th at 1:00 p.m. Eastern TimeGoldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CAFireside chat on Monday, June 12th at 4:40 p.m. Pacific TimeInterested parties may access a live and archived webcast of the presentation on the company’s website on the “Investors” section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus...

Continue reading

Advantage Solutions Names Meati CFO Jody Macedonio to Its Board of Directors

Jody Macedonio Jody MacedonioIRVINE, Calif., May 24, 2023 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage Solutions,” the “Company,” “we” or “our”) has appointed Jody Macedonio, chief financial officer for Meati, maker of animal-free meat alternatives, to its board of directors. Prior to joining Meati as the company’s top finance executive in 2022, Macedonio served as chief financial officer of Chobani. She previously served in chief financial officer roles at 8th Avenue Food & Provisions and Dean Foods. Earlier in her career, she held finance positions at Henkel AG, PepsiCo Inc. and Nestlé/Alcon Laboratories. Her strategic perspective and track record for deploying smart cost controls will bring added value to Advantage Solutions’ business transformation efforts, which include positioning the Company...

Continue reading

Rocky Mountain Chocolate Factory Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

– Unveils Strategic Transformation Plan to Accelerate Growth and Profitability – – New Investor Presentation Published on the Company’s Website – DURANGO, Colo., May 24, 2023 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we” or “RMCF”), a leading manufacturer and international franchiser of gourmet chocolates and other confectionary products, today reported financial and operating results for the three months and full year ended February 28, 2023. The Company will hold its conference call today at 8:30 a.m. Eastern time. “After spending the past several months conducting a full review of our business, I’m excited to announce and roll out our Strategic Transformation Plan,” said Rob Sarlls, CEO of Rocky Mountain Chocolate Factory. “The plan...

Continue reading

Republic of Iceland – Tender Offer Results Announcement

NOT FOR DISTRIBUTION IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT 24 May 2023. The Republic of Iceland (the “Offeror“) announces today the results of its invitation to holders of its €500,000,000 0.100 per cent. Notes due 20 June 2024 (ISIN: XS2015295814) (of which €500,000,000 in aggregate nominal amount is outstanding as at the date hereof) (the “Notes“) to tender their Notes for purchase by the Offeror for cash (such invitation, the “Offer“). The Offer was announced on 16 May 2023 and was made on the terms and subject to the conditions contained in the tender offer memorandum dated 16 May 2023 (the “Tender Offer Memorandum“) prepared by the Offeror in connection with the Offer. Capitalised terms used in this announcement but not defined have the meaning...

Continue reading

The Children’s Place Reports First Quarter 2023 Results

Reports Q1 GAAP EPS of ($2.33) versus $1.43 in Q1 2022 Reports Q1 Adjusted EPS of ($2.00) versus $1.05 in Q1 2022 Expects Double-Digit Operating Margin and Adjusted EPS of Over $5.00 in the Back Half of 2023 SECAUCUS, N.J., May 24, 2023 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty apparel retailer in North America, today announced financial results for the first quarter ended April 29, 2023. Jane Elfers, President and Chief Executive Officer, announced, “Our first quarter results were negatively impacted by the ongoing macro-tension which resulted in outsized pressure on our core customer by limiting their purchasing power.”  Ms. Elfers continued, “Our Easter assortments from both our TCP and Gymboree brands performed exceptionally well. Our digital sales trend significantly...

Continue reading

Ebix Signs Debt Extension Amendment

JOHNS CREEK, Ga., May 24, 2023 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: “Ebix”), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, healthcare, and e-learning industries, announced that it has signed an amendment (“Amendment No. 14”) to its existing credit agreement, extending the maturity date to September 30, 2023. Amendment No. 14 provides for, among other things, an extension of the maturity date for both the revolving line of credit (the “Revolver”) and the term loan (the “Term Loan”) each as existing under the Credit Agreement. It was conditioned, among other things, upon the Company (i) making a $5,000,000 payment of the Term Loan by June 30, 2023 and (ii) paying a customary consent fee which will be payable over time and partially waived if certain conditions are met. Amendment...

Continue reading

Form 8.3 – [EMIS Group plc – 23 05 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and TEL AVIV, Israel, May 24, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, has released its financial results for the quarter ended March 31, 2023. “The Company is successfully achieving key milestones for our investigational ExoPTEN drug and, in parallel, developing an exosome therapy platform that can be widely used by the medical industry to address many other illnesses,” Dr. Lior Shaltiel, CEO of NurExone. “We believe that the hybrid product-platform model will drive revenue through partnerships, licensing, and commercialization.” Key Business Highlights Intellectual Property Portfolio...

Continue reading

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-Year First Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-Year Solid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDA Growth of Over 30% Year-over-Year Announced $60 Million Private Placement with FIMI Opportunity Funds Received FDA Approval to Manufacture CYTOGAM® at the Company’s Israeli Facility; Expected to Positively Impact Plant Utilization and Efficiency Conference Call and Live Webcast Today at 8:30 AM ETREHOVOT, Israel and Hoboken, N.J., May 24, 2023 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company, with a portfolio of marketed products indicated for rare and serious conditions...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.